JPMorgan: Buy into the biotech bear market

Share
Pedro Castellano | Getty Images

The biotech sector plunged 13 percent last week sparked by Hillary Clinton's comments on high drug pricing and her plan for greater regulation of the sector.

Investors are wondering what's next for life sciences stocks as they are now in bear market territory, down 22 percent from July's highs.

JPMorgan reached out to fund managers to find out their current concerns and analyze the prospects for the biotech sector.

Here are the key takeaways in its note to clients sent Monday.

More In Investing

CNBC ProWhat to expect from Ark Invest's coming 'ARKX' ETF, which ignited a rally for pure-play space stocks
CNBC ProThese surprises could change the story for the stock market in 2021, Credit Suisse says